Drug Profile
Research programme: antimicrobial immunoconjugates - Cidara Therapeutics
Alternative Names: Antiviral Fc-Conjugates; CD 201; CoV AVC; HIV AVC; RSV AVCLatest Information Update: 11 May 2020
Price :
$50
*
At a glance
- Originator Cidara Therapeutics
- Class Antibacterials; Antiretrovirals; Antivirals; Drug conjugates; Immunoconjugates; Immunoglobulin Fc fragments
- Mechanism of Action Immunomodulators; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections; HIV infections; Respiratory syncytial virus infections
- Discontinued Gram-negative infections
Most Recent Events
- 05 May 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) before May 2020 (Cidara Therapeutics pipeline, May 2020)
- 05 May 2020 Preclinical trials in COVID-2019 infections in USA (Parenteral) before May 2020 (Cidara Therapeutics pipeline, May 2020)
- 05 May 2020 Preclinical trials in HIV infections (Prevention) in USA (Parenteral) before May 2020 (Cidara Therapeutics pipeline, May 2020)